ASH 2022

Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL

Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.

ASH 2022: MCL Trials Break New Ground, May Change Practice

Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.

ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.

Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death

Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.

AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”

AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.

ASH 2022: New Findings in CLL

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

Dexamethasone-Sparing Regimen Shows Promise in Frail Patients With MM

A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.

Frontline Regimens for MM Are Similar Across the World; Later Lines of Treatment Vary

Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.

ASH 2022: Trials Show Promising Results in Follicular Lymphoma

Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.

PTCy Plus Tacrolimus and MMF “Should Be Standard” GVHD Prophylaxis in RIC PBSCT

PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.

Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL

Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.

Blinatumomab-Based Consolidation Deemed New Standard Care for Adults With MRD-Negative B-ALL

Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.

HDC-ASCT Improves Survival vs Chemoimmunotherapy in Primary CNS Lymphoma

High-dose chemotherapy plus transplant improved outcomes compared with chemoimmunotherapy in a phase 3 trial of patients with primary CNS lymphoma.

Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma

Isatuximab plus carfilzomib, lenalidomide, and dexamethasone can produce deep responses in patients with high-risk, newly diagnosed multiple myeloma, a phase 2 trial suggests.

Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study

Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.

Age-Adapted Regimen “Highly Effective” for Elderly Patients With PCNSL

Age-adapted induction followed by high-dose chemoimmunotherapy and autologous transplant has shown promise for treating elderly, fit patients with primary central nervous system lymphoma.

Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML

Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.

Glofitamab Can Provide Lasting Remissions in Heavily Pretreated Large B-Cell Lymphoma

Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.

Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma

Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.

Less May Be More When Treating Newly Diagnosed AML

Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.